retatrutide triple agonist glp-1 gip glucagon phase 2 obesity Targeting GLP-1, & GCG in and Type Diabetes Research A review of an investigational

Those taking SGLT2 inhibitors alongside GLP-1/GIP medications face additional risks, including increased urination and potential for euglycemic diabetic ketoacidosis if severely dehydrated

In laboratory research, Tirzepatide has been studied for: Appetite regulation pathways Insulin-response signaling Metabolic efficiency Body composition research Glucose metabolism studies Researchers are particularly interested in how combining GLP-1 and GIP activity may influence broader metabolic outcomes compared to single-pathway compounds

Tirzepatide is a peptide molecule that is produced synthetically that acts on both GIP and GLP-1 receptors as a receptor agonist

Now thats deep wellness

These are prepared by licensed compounding pharmacies and require a medical consultation before dispensing